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Abstract
Background: The potential for faster detection of
human herpes viruses using PCR compared to other
methods is undisputed. However, because of fear of
contamination, the clinical implication of nucleic
amplification methods in routine laboratories is not
widespread. Herpes viruses cause a wide spectrum of
diseases and can cause morbidity and mortality in
immune-compromised patients. Using real-time PCR,
most of the problems associated with PCR (contami-
nation, cumbersome detection, and rather expensive
tests) are solved, and a rapid, economical, and – most
importantly – closed system is at hand.
Methods: We evaluated work procedures in our lab-
oratory that enable the routine diagnosis of viral
infections with high accuracy and rapid turn-around
time. In parallel, inherent problems usually associ-
ated with PCR testing, especially cross-contamina-
tion could be suppressed to a minimum. The start
of the work flow process begins with an automated
nucleic acid extraction procedure that yields high
quality DNA. A common – internally and externally
controlled – PCR program for all six viruses allows
rapid sample turn around.
Results: In all, 7500 analyses for human herpes virus
infection were performed in the last 5 years. Results
for various different specimens were produced within
24 h. Contamination occurred rarely and could be
ameliorated easily. The use of internal controls iden-
tified rare PCR-inhibited samples. The detection limits
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for our assays are markedly below the clinically rel-
evant range.
Conclusions: Our workflow allowed rapid, cost-effi-
cient, and labor saving routine diagnostic detection of
viral infections.
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Introduction
Real-time PCR enables rapid analyses of clinical sam-
ples and can be streamlined for routine use in the
clinical setting. For the past 5 years, we have utilized
this technology for the diagnoses of viral infections.
In all, we have performed over 30,000 analyses for
viral infection wherpes viruses (HVs), respiratory virus-
es, hepatitis C virusx using an optimized routine pro-
tocol. Here, we detail our experience with various
specimens, work procedures, and results for diagno-
ses of six human HVs.
These viruses cause a spectrum of diseases that
are self-limiting usually but can be reactivated in
immune-compromised patients (1–5). Cytomegalo-
virus (CMV), varicella-zoster virus (VZV), and herpes
simplex virus (HSV) type 1 and 2 can cause enceph-
alitis, meningitis, myelitis, or polyradiculitis (6). The
human HVs are an important cause of central nervous
system (CNS) disease in human immunodeficiency
virus (HIV) infected patients.
Generalized or disseminated infections may occur
because of neoplasia, organ transplantation, and
inherited or acquired immunodeficiency disease.
These viruses can then cause life-threatening dis-
eases including pneumonia and encephalitis. Infec-
tions caused by different HVs may be clinically
indistinguishable in AIDS patients, and simultaneous
CNS infections caused by different HVs have occa-
sionally been described (2). A multiplex PCR assay
with the ability to detect simultaneously different HVs
in cerebrospinal fluid (CSF) might therefore be a use-
ful and practical approach to the differential diagnosis
of CNS disorders. Such a method has the advantage
of rapidity and economy, particularly in cases where
more than one HV may be involved. In addition, it
offers the possibility of detecting co-infections with
several HVs.
For the clinician, a rapid and meaningful result from
the laboratory is needed (7–10). The gold standard of
viral detection, i.e., virus isolation in cell culture, is too
slow and cumbersome and not useful for CSF (11, 12).
Other detection methods, such as enzyme linked
immunosorbent assays (ELISA) and latex agglutina-
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Table 1 Percentage of positive specimens with diagnosed human herpes viruses infections.
Specimen CMV, % HHV6, % HSV, % VZV, % EBV, %
Serum 60 60 2 3 57
Urine 21
NF 19 1 15
Liquor 40 3 3
Blister 94 94
Sputum 28
The percentage of the various specimens with positively diagnosed human herpes viruses infections are shown. CMV, cyto-
megalovirus; HHV6, human herpes virus 6; HSV, herpes simplex virus; VZV, varicella-zoster virus; EBV, Epstein-Barr virus;
NF, nasal wash fluid.
tion, nucleid acid probe, and fluorescent antibody
methods generally fail when low titers of HVs are
present in specimens that are inoculated into cell cul-
tures (13).
In contrast, real-time PCR provides qualitative and
quantitative results within several hours that are inter-
nally and externally controlled (14, 15). Thus, PCR has
become a valuable tool for the diagnosis of viral infec-
tion because of its speed, specificity, and sensitivity.
Materials and methods
PCR
Two hundred mL of each specimen was subjected to extrac-
tion of viral nucleic acids using the Magna Pure automated
extractor (Roche Diagnostics, Vienna, Austria) on the day of
arrival. For HSV and VZV requested by the dermatological
ward, we received microscope slides with mucocutaneous
smears on it. A cotton swab wetted in 400 mL of buffer was
used to wipe the smear in order to absorb the specimen. The
swab was then transferred back into the vial with the remain-
ing buffer. Pressing the swab against the wall of the tube
(containing the remaining buffer) allowed most of the
adsorbed liquid with the dissolved specimen to be placed
back into the tube. Next, 200 mL were used for extraction
using the Magna Pure.
The extraction quality for the diverse specimens was eval-
uated by adding standards directly into negative specimens
and comparing the results with standards added directly to
the PCR mixes. External quality assessment programs
(German Institute for Standardization and Documentation in
the Medical Laboratory – INSTAND) for all the viruses exam-
ined were performed continuously. With this program, four
samples each of the viruses to be tested (all HVs) are sent
to laboratories for quantitative analyses of viral loads. For
the past 5 years, we have successfully fulfilled the criteria for
this assessment program and received accreditation to con-
duct these analyses.
Five mL aliquots of the extracted nucleic acids were sub-
jected to real-time PCR on a LightCycler (Roche Diagnostics,
Vienna, Austria) by mixing with the respective virus master
mix reagents according to the manufacturer’s instructions.
Reagent kits utilized for the virus specific PCRs were: ARTUS
EBV LC PCR kit, ARTUS CMV LC PCR kit, ARTUS HSV LC
PCR kit, ARTUS EBV LC PCR kit, ARTUS VZV LC PCR kit (QIA-
GEN, Berlin, Germany), and HHV6 LightMix kit/TIB MolBio,
IPC mix (TIB MolBio GmbH, Berlin, Germany), each contain-
ing reagents and enzymes for the specific amplication of the
genome and for the direct detection of the specific amplicon
with the LightCycler.
A denaturation step (10 min at 958C) was followed by 5 s
at 958C, 5 s at 658C down to 558C with a step size of 18C/
cycle, and 15 s at 728C, for 10 cycles. Forty cycles of 5 s at
958C, 5 s at 558C, and 15 s at 728C followed with detection at
558C. All ramp rates were 208C/s.
All reactions included internal controls; standards and
external positive and negative controls were run in parallel.
A calibration curve for quantitation was created using the
standards that were supplied. Because external quantifica-
tion standards with international units are not available for
the viruses assayed, we utilized the standards of the detec-
tion reagents from QIAGEN for quantitative results
expressed as viral copies/mL.
Results
Over the past 5 years, we have performed 7500 anal-
yses for HVs, ;2200 for HSV, 1800 for Epstein-Barr
virus (EBV), 1700 for VZV, and lesser amounts for
CMV (1200) and human herpes virus 6 (HHV6) (500).
Various specimens were sent from the wards accord-
ing to their needs (see Table 1). The gender distribu-
tion of patients was nearly equal, and patient ages
ranged from 1 day to 90 years. All analyses (including
further 25,000 respiratory and hepatitis C viral detec-
tions) were performed by two laboratory technicians.
For HSV (type 1 and 2), most analyses were per-
formed for patients from the dermatological ward.
Most were performed using material from blisters,
with less from urine and serum. Likewise, most
requests for the VZV diagnosis came from this ward.
The percentages of positive results were 15% for
HSV 1/2, and 12% for VZV.
The other viral diagnoses were requested primarily
by our children’s department.
Historically, for EBV, the laboratory performed a
quick test for anti EBV IgG and IgM. Following the
introduction of the PCR test, the number of serologic
diagnoses did not vanish completely, allowing com-
parison between the two test formats. Of the 270 PCR
positive sera, ;120 were also tested for antibodies.
Half of these came at times when overt symptoms
could be seen but no immunological response had
started. Clearly, the results of direct antigen detection
were more informative in these cases.
For EBV, 15% of specimens were positive and for
CMV, 7% of specimens were positive. The least
amount of positive results (2%) was for HHV6 infec-
tion, we received requests for this test 500 times only.
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Table 2 Analyses of human herpes viruses over the past
5 years.
Herpes viruses Analyses Positive results n, %
HSV (type 1 and 2) 2184 315 (15)
EBV 1835 270 (12)
VZV 1676 211 (15)
CMV 1229 93 (7)
HHV6 469 9 (2)
Total 7393 898 (12)a
aBecause the majority of patients had more than one virus
diagnosis requested, the overall positive rate related to the
number of patients was higher (21%). HSV, herpes simplex
virus; EBV, Epstein-Barr virus; VZV, varicella-zoster virus;
CMV, cytomegalovirus; HHV6, human herpes virus 6.
Figure 1 Copy numbers per mL of specimen for the viruses (except HHV6) tested in the various specimens.
The highest viral load can be found in material from blisters for HSV and VZV. For HSV2, only material from blisters was
sent to the laboratory. NF, nasal wash fluid; CMV, cytomegalovirus; EBV, Epstein-Barr virus; VZV, varicella-zoster virus; HSV,
herpes simplex virus.
We did not find co-infection with two or more virus-
es. However, because the majority of patients had
more than one request for viral detection, the overall
positive rate related to the number of patients was
higher (21%) (Table 2).
Figure 1A–D shows the copy numbers per mL of
specimen for the viruses (except HHV6) tested. These
amounts are informative and show the relative mag-
nitude of the various specimens. The highest viral
load can be found in material from blisters of HSV and
VZV. Up to 1010 viral copies could be found. In serum,
the viral copy numbers usually were in the range of
104–105/mL, whereas in CSF, copy numbers up to
108/mL were found. These data show that the largest
proportion of specimens from our hospital have copy
numbers many orders of magnitude higher than the
test limits (HSV: 1 copy/mL, CMV: 0.5 copies/mL, EBV:
5 copies/mL, VZV: 0.8 copies/mL).
The efficiency of our extraction apparatus was eval-
uated using positive samples that were extracted in
duplicate. After an initial extraction step using several
of the same samples, the resulting liquid was pooled
and aliquoted. One aliquot was again extracted. The
supernatants of the first and second extraction were
quantified using PCR. The first extraction was used as
the efficiency test standard.
The second extract was compared with it and the
efficiency was calculated. The average efficiency of
extraction was found to be 60%, which is excellent
according to expected results of automated extraction
procedures (16, 17).
Discussion
The potential for faster detection of HVs by PCR as
compared to other methods is undisputed. Quantita-
tive PCR assays allow monitoring of the kinetics of the
viral infection in order to distinguish between acute
and persistent infections and to estimate the success
of antiviral therapy (18–20). These viruses can cause
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life-threatening diseases including pneumonia and
encephalitis in immune-compromised patients. The
human HVs are important causes of CNS disease in
HIV-infected patients. CMV, VZV, and HSV types 1 and
2 can cause encephalitis, meningitis, myelitis, or poly-
radiculitis (6).
Such neurological complications are common in
HIV-infected patients. Unfortunately, clinical, CSF, and
neuroimaging findings are frequently non-specific.
Furthermore, routine CSF tests such as viral culture
have a very low diagnostic yield.
In recent years, PCR analysis of CSF has contributed
substantially to improving the diagnosis and clinical
management of the CNS complications in HIV-infect-
ed patients (1, 21).
However, because of fear of contamination, the
clinical implication of nucleic amplification methods
in routine laboratories is not yet widespread. Using
real-time PCR, most of the problems associated with
PCR (contamination, cumbersome detection, and
rather expensive tests) are solved, and a rapid, eco-
nomical (considering the reduced workload), and –
most importantly – closed system is available. The
use of internal controls simplified the assay protocol
and allowed monitoring of sample adequacy (10, 22,
23).
The remaining areas of cross contamination need
to be monitored carefully. Separate rooms for speci-
men extraction and target loading need to be in place
and must be separated from the master mix prepara-
tion room (24).
With the vast number of analyses executed and the
known inherent problems of PCR, it is of no surprise
that we did have problems with contamination. How-
ever, questionable results were ameliorated within
2–3 days. The use of negative controls gives a clear
indication of the quality of results. Of further help is
the fact that many tests for a given virus were done
simultaneously and contamination showed up as
increased numbers of positive samples at a same lev-
el of target concentration. To restore the quality of the
diagnoses, reagents for extraction and/or PCR were
discarded immediately.
We only employ reagents for these analyses that
are certified for in vitro diagnosis (IVD) (CE marked).
These pose a slight drawback to reagents with hybrid-
ization probes that can be examined further using
melting curve analysis. Using this, another degree of
certainty would be introduced in the assay because
negative test results due to sequence changes in the
probe sequences could be uncovered. Unfortunately,
CE certified tests with this option are not on the
market.
The specificity and sensitivity of PCR tests are high-
ly relevant (25). The tests used show no cross-reac-
tivity and can detect very low copy numbers. Our
results indicate that the largest proportion of speci-
mens from our hospital have copy numbers many
orders of magnitude higher than the test limits.
Any serological response of a patient to an infection
by the viruses examined requires days or weeks. It is
well recognized that serological tests are needed in
many clinical circumstances (26). For the quick differ-
entiation of genital herpes (HSV1, HSV2), the culprit
origin of blisters (HSV1/HSV2, VZV), involvement of
CSF, or differential diagnosis of rashes (among
others), rapid tests are needed urgently. This could be
seen clearly in our tests for EBV infections. Half of the
PCR positive patients had no immunological response
when they presented with overt symptoms.
We can provide test results for the clinicians within
24 h using two laboratory technicians only. This is
due to automated sample extraction and a common
temperature cycling program on the real-time PCR
machine for all six viruses. Within a short time, an
online apparatus will be available. This means that
primary vials will be handled by the automated
extraction with a sample list provided directly by the
laboratory data system. Using automated sample
pipetting, the extracted nucleic acids will be prepared
for PCR, and resultant PCR data will be directed back
to the laboratory data system. The separate building
blocks for such an integrated work flow are already
on the market. Clinical chemistry laboratories like
ours will implement such solutions in the near future.
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